Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Hauser

Showing results (71-80 of 266) with videos related to

Pageof 27
Sort By:
Expert Opinion on Pharmacotherapy|August 28, 2004
Botulinum toxin A for the treatment of cervical dystoniaTheresa A Zesiewicz, William Stamey, Kelly L Sullivan, et al.
Parkinsonism & Related Disorders|December 22, 2020
The challenge of developing adenosine A<sub>2A</sub> antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenantPeter A LeWitt, Stephen D Aradi, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 13, 2010
Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuationsBonnie P Hersh, Nancy L Earl, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 13, 2014
Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's diseaseRobert A Hauser, Dee Silver, Azhar Choudhry, et al.
Cases Journal|October 16, 2009
Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case seriesKapil D Sethi, Robert A Hauser, Stuart H Isaacson, et al.
Clinical Neuropharmacology|August 3, 2005
Levetiracetam-induced parkinsonism in a Huntington disease patientTheresa A Zesiewicz, Juan Sanchez-Ramos, Kelly L Sullivan, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 25, 2019
Dyskinesia mattersM Angela Cenci, Sara Riggare, Rajesh Pahwa, et al.
Clinical Parkinsonism & Related Disorders|July 27, 2023
Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatmentStuart H Isaacson, Robert A Hauser, Rajesh Pahwa, et al.
Neurology|June 12, 2002
Bilateral human fetal striatal transplantation in Huntington's diseaseRobert A Hauser, Paul R Sandberg, Thomas B Freeman, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 17, 2020
Reply to: Letter to Editor by Chaudhuri, Jenner, AntoniniRobert A Hauser, David Eidelberg, Rajesh Pahwa, et al.
Pageof 27

Showing results (71-80 of 266) with videos related to

Sort By:
Pageof 27
Expert Opinion on Pharmacotherapy|August 28, 2004
Botulinum toxin A for the treatment of cervical dystoniaTheresa A Zesiewicz, William Stamey, Kelly L Sullivan, et al.
Parkinsonism & Related Disorders|December 22, 2020
The challenge of developing adenosine A<sub>2A</sub> antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenantPeter A LeWitt, Stephen D Aradi, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 13, 2010
Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuationsBonnie P Hersh, Nancy L Earl, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 13, 2014
Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's diseaseRobert A Hauser, Dee Silver, Azhar Choudhry, et al.
Cases Journal|October 16, 2009
Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case seriesKapil D Sethi, Robert A Hauser, Stuart H Isaacson, et al.
Clinical Neuropharmacology|August 3, 2005
Levetiracetam-induced parkinsonism in a Huntington disease patientTheresa A Zesiewicz, Juan Sanchez-Ramos, Kelly L Sullivan, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 25, 2019
Dyskinesia mattersM Angela Cenci, Sara Riggare, Rajesh Pahwa, et al.
Clinical Parkinsonism & Related Disorders|July 27, 2023
Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatmentStuart H Isaacson, Robert A Hauser, Rajesh Pahwa, et al.
Neurology|June 12, 2002
Bilateral human fetal striatal transplantation in Huntington's diseaseRobert A Hauser, Paul R Sandberg, Thomas B Freeman, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 17, 2020
Reply to: Letter to Editor by Chaudhuri, Jenner, AntoniniRobert A Hauser, David Eidelberg, Rajesh Pahwa, et al.
Pageof 27